Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2016

Open Access 01-12-2016 | Study protocol

Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial

Authors: Debbie Tallon, Nicola Wiles, John Campbell, Carolyn Chew-Graham, Chris Dickens, Una Macleod, Tim J. Peters, Glyn Lewis, Ian M. Anderson, Simon Gilbody, William Hollingworth, Simon Davies, David Kessler

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant. This paper describes the protocol for a randomised controlled trial (MIR) to investigate the extent to which the addition of the antidepressant mirtazapine is effective in reducing the symptoms of depression compared with placebo in patients who are still depressed after they have been treated with a selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI) for at least 6 weeks in primary care.

Methods/Design

MIR is a two-parallel group, multi-centre, pragmatic, placebo controlled, randomised trial with allocation at the level of the individual. Eligible participants are those who: are aged 18 years or older; are currently taking an SSRI/SNRI antidepressant (for at least 6 weeks at an adequate dose); score ≥14 on the Beck Depression Inventory (BDI-II); have adhered to their medication; and meet ICD-10 criteria for depression (assessed using the Clinical Interview Schedule-Revised version).
Participants who give written, informed consent, will be randomised to receive either oral mirtazapine or matched placebo, starting at 15 mg daily for 2 weeks and increasing to 30 mg daily thereafter, for up to 12 months (to be taken in addition to their usual antidepressant). Participants, their GPs, and the research team will all be blind to the allocation. The primary outcome will be depression symptoms at 12 weeks post randomisation, measured as a continuous variable using the BDI-II.
Secondary outcomes (measured at 12, 24 and 52 weeks) include: response (reduction in depressive symptoms (BDI-II score) of at least 50 % compared to baseline); remission of depression symptoms (BDI-II <10); change in anxiety symptoms; adverse effects; quality of life; adherence to antidepressant medication; health and social care use, time off work and cost-effectiveness. All outcomes will be analysed on an intention-to-treat basis.
A qualitative study will explore patients’ views and experiences of either taking two antidepressants, or an antidepressant and a placebo; and GPs’ views on prescribing a second antidepressant in this patient group.

Discussion

The MIR trial will provide evidence on the clinical and cost-effectiveness of mirtazapine as an adjunct to SSRI/SNRI antidepressants for patients in primary care who have not responded to monotherapy.

Trial registration

EudraCT Number: 2012-000090-23 (Registered January 2012); ISRCTN06653773 (Registered September 2012)
Literature
1.
Mathers C, Loncar D. Updated projections of global mortality and burden of disease, 2002—2030: data sources, methods and results (working paper). Geneva: WHO; 2005.
2.
Prescribing and Medicines Team, Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2004—14.2015.
3.
Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatr. 2006;163:28–40.CrossRefPubMed
4.
National Institute for Clinical Excellence. Clinical Guideline 90. Depression: management of depression in primary and secondary care. London 2009.
5.
Connolly K, Thase M. If at first you don’t succeed: a review of evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64.CrossRefPubMed
6.
Nelson J, Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatr. 2009;166:980–91.CrossRefPubMed
7.
8.
Zhou X, Ravindran A, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487–e98.CrossRefPubMed
9.
Cha D, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13(11):1587–98.CrossRefPubMed
10.
Fava M, Rush A, Wisniewski S, Nierenberg A, Alpert J, McGrath P, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatr. 2006;163(7):1161–72.CrossRefPubMed
11.
Carpenter L, Yasmin S, Price L. A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. Biol Psychiatry. 2002;51(2):183–8.CrossRefPubMed
12.
Blier P, Gobbi G, Turcotte J, de Montigny C, Boucher N, Hébert C, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457–65.CrossRefPubMed
13.
Blier P, Ward H, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatr. 2010;167:281–8.CrossRefPubMed
14.
Rush A, Trivedi M, Stewart J, Nierenberg A, Fava M, Kurian B, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatr. 2011;168(7):689–701.CrossRefPubMed
15.
Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734–50.CrossRefPubMed
16.
World Psychiatric Association. Symposium on therapy resistant depression. Pharmacopsychiatry. 1974;7:69.
17.
18.
Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381(9864):375–84.CrossRefPubMed
19.
ICD-10 World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: 1992.
20.
Thomas L, Kessler D, Campbell J, Morrison J, Peters T, Williams C, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract. 2013;63:852–8.CrossRef
21.
National Collaborating Centre for Mental Health. The NICE guideline on the treatment and management of depression in adults updated edition. London: The British Psychological Society and The Royal College of Psychiatrists; 2010.
22.
Thomas L, Abel A, Ridgway N, Peters T, Kessler D, Hollinghurst S, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the CoBalT protocol. Contemp Clin Trials. 2012;33(2):312–9.CrossRefPubMed
23.
Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMed
24.
George C, Peveler R, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Psychopharmacol. 2000;50(2):166–71.CrossRef
25.
Beck A, Steer R, Brown G. Manual for the Beck Depression Inventory-II. San Antonio: Psychological Corporation; 1996.
26.
Lewis G, Pelosi A, Araya R, Dunn G. Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med. 1992;22(2):465–86.CrossRefPubMed
27.
28.
Spitzer R, Kroenke K, Williams J, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.CrossRefPubMed
29.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.CrossRefPubMedPubMedCentral
30.
Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195(3):202–10.CrossRefPubMed
31.
Saunders J, Aasland O, Babor T, de la Fuente J, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption — II. Addiction. 1993;88(6):791–804.CrossRefPubMed
32.
Brown S, Thorpe H, Hawkins K, Brown J. Minimization — reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med. 2005;24:3715–27.CrossRefPubMed
33.
European Commission Enterprise and Industry Directorate-General. The rules governing medicinal products in the European Union. Brussels 2010.
34.
Schulz K, Altman DG, Moher D. Consort Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):716–32.CrossRef
35.
36.
van Buuren S, Boshuizen H, Knook D. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–94.CrossRefPubMed
37.
Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res. 2005;14(4):369–95.CrossRefPubMed
38.
Fischer K, Goetghebeur E, Vrijens B, White I. A structural mean model to allow for noncompliance in a randomized trial comparing two active treatments. Biostatistics. 2011;12(2):247–57.CrossRefPubMed
39.
White I, Kalaitzaki E, Thompson S. Allowing for missing outcome data and incomplete uptake of randomised interventions, with application to an Internet-based alcohol trial. Stat Med. 2011;30(27):3192–207.CrossRefPubMedPubMedCentral
40.
Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, et al. Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet. 2009;374:628–34.CrossRefPubMed
41.
42.
43.
Department of Health. 2009—10 reference costs publication. 2011.
44.
Lensberg BR, Drummond MF, Danchenko N, Despiégel N, François C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565–73.CrossRefPubMedPubMedCentral
45.
Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415–30.CrossRefPubMed
46.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013.
47.
Manaca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487–96.CrossRef
48.
Bradley E, Curry L, Devers K. Qualitative data analysis for health services research: developing taxonomy, themes, and theory. Health Serv Res. 2007;42(4):1758–72.CrossRefPubMedPubMedCentral
49.
May C, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, et al. Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci. 2009;4:29.CrossRefPubMedPubMedCentral
50.
51.
Walsh B, Seidman S, Sysko R, Gould M. Placebo response in studies of major depression. JAMA. 2002;287(14):1840–7.CrossRefPubMed
Metadata
Title
Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial
Authors
Debbie Tallon
Nicola Wiles
John Campbell
Carolyn Chew-Graham
Chris Dickens
Una Macleod
Tim J. Peters
Glyn Lewis
Ian M. Anderson
Simon Gilbody
William Hollingworth
Simon Davies
David Kessler
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1199-2

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue

Study protocol

Regional Anesthesia for Painful Injuries after Disasters (RAPID): study protocol for a randomized controlled trial

Study protocol

Steroids in fluid and/or vasoactive infusion dependent pediatric shock: study protocol for a randomized controlled trial

Research

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study

Study protocol

The RESPITE trial: remifentanil intravenously administered patient-controlled analgesia (PCA) versus pethidine intramuscular injection for pain relief in labour: study protocol for a randomised controlled trial

Study protocol

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial

Study protocol

Polypharmacy in chronic diseases–Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial